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Abstract
Background: Leishmania spp. are sandfly transmitted protozoan parasites that cause a spectrum
of diseases in more than 12 million people worldwide. Much research is now focusing on how these
parasites adapt to the distinct nutrient environments they encounter in the digestive tract of the
sandfly vector and the phagolysosome compartment of mammalian macrophages. While data
mining and annotation of the genomes of three Leishmania species has provided an initial inventory
of predicted metabolic components and associated pathways, resources for integrating this
information into metabolic networks and incorporating data from transcript, protein, and
metabolite profiling studies is currently lacking. The development of a reliable, expertly curated,
and widely available model of Leishmania metabolic networks is required to facilitate systems
analysis, as well as discovery and prioritization of new drug targets for this important human
pathogen.
Description: The LeishCyc database was initially built from the genome sequence of Leishmania
major (v5.2), based on the annotation published by the Wellcome Trust Sanger Institute. LeishCyc
was manually curated to remove errors, correct automated predictions, and add information from
the literature. The ongoing curation is based on public sources, literature searches, and our own
experimental and bioinformatics studies. In a number of instances we have improved on the original
genome annotation, and, in some ambiguous cases, collected relevant information from the
literature in order to help clarify gene or protein annotation in the future. All genes in LeishCyc
are linked to the corresponding entry in GeneDB (Wellcome Trust Sanger Institute).
Conclusion: The LeishCyc database describes Leishmania major genes, gene products, metabolites,
their relationships and biochemical organization into metabolic pathways. LeishCyc provides a
systematic approach to organizing the evolving information about Leishmania biochemical networks
and is a tool for analysis, interpretation, and visualization of Leishmania Omics data (transcriptomics,
proteomics, metabolomics) in the context of metabolic pathways. LeishCyc is the first such
database for the Trypanosomatidae family, which includes a number of other important human
parasites. Flexible query/visualization capabilities are provided by the Pathway Tools software and
its Web interface. The LeishCyc database is made freely available over the Internet http://
www.leishcyc.org.
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Background
Protozoan parasites comprise a highly divergent group of
eukaryotes that cause a range of debilitating diseases in
humans, including malaria, leishmaniasis, African sleep-
ing sickness, and Chagas' disease. Leishmania  spp. are
sandfly transmitted protozoan parasites (family Trypano-
somatidae) and are the etiological agent of leishmaniasis.
Leishmaniasis refers to a spectrum of diseases ranging
from self-healing cutaneous lesions to debilitating muco-
cutaneous and lethal visceral infections. It is estimated
that more than 12 million people have active leishmania-
sis, and 350 million people are at risk, making Leishmania
the most important parasitic disease after malaria (World
Health Organization). No vaccines against leishmaniasis
exist; high toxicity and cost of current treatments and the
emergence of drug resistant parasite strains point to the
urgent need for novel drug targets.
A detailed understanding of Leishmania  metabolism
would open new avenues for the development of new
drugs, and also lead to a greater understanding of how
these parasites adapt to nutrient environments in the
sandfly and mammalian hosts. For example, the flagel-
lated promastigote stages of the parasite that develop in
the digestive tract of the sandfly vector obtain nutrients
from the sugar rich blood meal and plant saps upon
which the sandfly feeds [1]. In contrast, the mammalian
infective amastigote stages develop within the sugar poor
environment of the phagolysosome of macrophages and
some other phagocytic cells and may exploit a variety of
other carbon sources [2,3]. The recent sequencing of the
genomes of three Leishmania species (L. major, L. infantum,
L. braziliensis) has provided the first blueprints of the met-
abolic potential of these parasites [4-6]. Recently, a sys-
tems approach was used to generate a metabolic network
for the L. major Friedlin strain and make predictions about
essential genes and pathway robustness [7]. However,
more than 65% of the protein-encoding sequences in the
Leishmania  genome cannot yet be assigned a function
based on homology searches, and therefore it is likely that
in silico models will need to be substantially improved as
new metabolic pathways are identified.
The major database for Leishmania genomic data is the
GeneDB genome resource, established by the Sanger Insti-
tute [8-10], and soon to be accessible via the Eukaryotic
Pathogens Database Resource (EuPathDB). GeneDB was
initially developed to store genomic data for T. brucei, L.
major, and S. pombe, and was later expanded to include
curated data for a number of other organisms, including
bacteria, fungi, and protozoa [9,10]. GeneDB allows gene
finding, protein feature predictions, and searches against
customized and protein domain/families databases. It
provides a number of useful tools for querying genomic
data, including plain text searches, BLAST searches, regu-
lar expressions enabled motif searches, and AmiGO
browsing of genes [10]. Although GeneDB is an important
resource for the Leishmania community, it does not inte-
grate genomic data into biochemical networks [8-10].
Kyoto Encyclopedia of Genes and Genomes (KEGG) inte-
grates genomic, chemical, and functional information for
a number of organisms [11,12]. Release 48.0 of KEGG
contains 91,648 reference pathways, and genomic infor-
mation from 100 eukaryotes, 709 bacteria, and 52
archaea. While this top-down approach facilitates integra-
tion of all available information and easy visual inspec-
tion of pathways in different organisms, the lack of
organism specialization often means that, for more
obscure organisms specific information is not easily acces-
sible, and in some cases, not included. A different
approach has been taken by the BioCyc project [13],
which is built around the ontology developed to describe
biological functions on a cellular and molecular level
[14]. In contrast to the centralized approach used by the
KEGG database, the BioCyc databases are highly distrib-
uted. The BioCyc project consists of MetaCyc (a reference
database of metabolic pathways [15-18]) and a set of
organism-specific databases which describe genes, gene
products, metabolites, their relationships and organiza-
tion into metabolic pathways [13]. MetaCyc contains
experimentally elucidated metabolic pathways from a
variety of organisms [17,18]. A number of organism-spe-
cific BioCyc databases are under active development and
curation [16,19-24].
In this work, we report on the development and use of
LeishCyc, the pathway/genome database for L. major
based on the BioCyc ontology. The initial build of Leish-
Cyc was based on the genome sequence of L. major [4] and
the Wellcome Trust Sanger Institute genome annotation.
Subsequently, LeishCyc was curated based on literature
searches and our own experimental and bioinformatics
studies. This included: (a) annotation and assignment of
additional enzymes; (b) checking, deletion, creation, and
modification of existing reactions and pathways; and (c)
assignment of evidence codes and literature citations.
Construction and content
Initial build
The L. major Friedlin genome is 32.8 Mb in size, with a
karyotype of 36 chromosomes. The genome data (version
5.2) was downloaded from the Sanger Institute public
database ftp://ftp.sanger.ac.uk/pub/databases/
L.major_sequences/. The Pathway Tools component of
PathoLogic was used to build the initial version of Leish-
Cyc from the genomic data [25]. PathoLogic requires the
sequence for each genomic element (a chromosome in
this case), and associated annotation file. The chromo-
some sequences were extracted from 36 corresponding
Sanger XML files, and were edited and reformatted withBMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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in-house developed programs. The L. major genome anno-
tation originally provided by Sanger was in the Artemis
format, and we used Artemis to convert the annotation
file for each chromosome into the GenBank format. The
resulting GenBank files were edited to add headers and
subsequently the automated trial and build procedure was
performed in PathoLogic.
The L. major genome contains 8283 genes predicted to
encode polypeptides. The Pathway Tools software
matched 574 of these genes to MetaCyc reactions based
on the presence of an EC number in the gene annotation.
Another 267 polypeptides, where no EC number was sup-
plied, were matched to reactions based on their annotated
name. The automated build resulted in 841 enzymes pre-
dicted for L. major. After the initial build, the list of 'prob-
able enzymes' was constructed. Probable enzymes were
gene products predicted to be enzymes but which could
not be matched to any particular reaction by PathoLogic.
These entries were manually reviewed and assigned to
reactions where possible. There were 328 probable
enzymes predicted for L. major and 148 were assigned to
reactions by manual review.
Refinement and curation
Extensive manual curation of the database was performed
based on literature search, and in-house experimental and
bioinformatics studies. This included verification of
enzymes and reactions deduced from the original genome
annotation, refinements and improvement in the annota-
tion of genes, enzymes, reactions and pathways, assign-
ment of evidence codes, and inclusion of literature
citations. At present LeishCyc contains 1027 enzymes and
566 metabolites organized into 704 enzymatic reactions,
37 transport reactions, and 143 metabolic pathways
(Table 1).
Only pathways present in MetaCyc can be automatically
incorporated into the pathway database by Pathway Tools
[25]. As MetaCyc contains predominantly bacterial and
plant pathways, some pathways known to be present in
Leishmania spp. were not present in the initial LeishCyc
build. For example, MetaCyc lacked pathways involved in
the assembly of the major surface glycoconjugates of
Leishmania, including the biosynthesis of glycosylphos-
phatidylinositols (GPIs) and related glycolipids, and the
assembly of complex phosphoglycans on the cell surface
and secreted proteins and glycolipids [26]. These and
other new pathways were therefore manually created for
LeishCyc based on the literature references. In addition, it
was necessary to modify some of the automatically
imported pathways in order to accurately represent
known metabolic pathways in Leishmania spp. For exam-
ple, the pathways for dolichyl-diphosphooligosaccharide
and fatty acid biosynthesis were modified to reflect what
has been experimentally observed or predicted for Leish-
mania [27,28]. In total, 66 pathways were created or mod-
ified in LeishCyc [see Additional file 1]. We have also
added links between the LeishCyc pathways to show how
they connect to each other.
After the initial build of LeishCyc, it was necessary to
review the pathways and remove false-positive predic-
tions [19]. All pathways were reviewed, and those deemed
to be supported by weak evidence were removed. For
example, a pathway was removed if it did not contain any
enzymes that were unique to the pathway and there was
no experimental evidence for the pathway existence in the
Leishmania spp. In some cases, pathways were deleted and
replaced with Leishmania-specific pathways. For example,
two pathways for phospholipid biosynthesis were present
after the initial build (phospholipid biosyntheses I and
II). These were replaced with Leishmania-specific pathways
for phospholipid biosynthesis (ester phospholipid bio-
synthesis and ether phospholipid biosynthesis) [29,30].
In total, 128 pathways were removed from LeishCyc after
the initial build [see Additional file 2].
Our own experimental work was used to add and verify
some of the information present in LeishCyc. For exam-
ple, GC-MS analysis of polar metabolites from cultured L.
major  promastigotes revealed the presence of several
metabolites (i.e. glucitol and glycerol 2-phosphate) for
which exogenous sources or biosynthetic enzymes were
lacking, indicating the presence of new or unanticipated
reactions. Recent analyses of sugar phosphates using high
resolution Fourier-transform ion cyclotron resonance (FT-
ICR) mass spectrometry, identified a novel mannose
cyclic phosphate that is the primer for the major intracel-
lular reserve carbohydrate of Leishmania, linear polymers
of mannose which we have now termed mannogen
[31,32]. While none of the enzymes involved in the
assembly of the mannogen primer or downstream steps
Table 1: Summary of LeishCyc statistics after the initial 
automated build, and current status after manual curation.
Category Initial build Current status
Genome size (bp) 32,816,678 32,816,678
Polypeptides 8284 8286
tRNAs 83 83
Pathways 215 143
Enzymatic Reactions 1062 704
Transport Reactions 6 37
Enzymes 841 1027
Transporters 23 47
Compounds 795 566
Protein Complexes 2 6
Citations 117 317BMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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have been identified, the biochemically delineated steps
have been incorporated into LeishCyc.
Targeted bioinformatics studies were used to aid curation
and improve the LeishCyc annotations. For example, the
original genomic annotation implied only two enzymes
to participate in the pathway 'dolichyl-diphosphooli-
gosaccharide biosynthesis'. Literature review has shown
that this pathway is indeed present in Leishmania  spp.
[27], and hence our bioinformatics studies were directed
towards identifying genes coding for missing enzymes of
this pathway. We used hidden Markov models (HMMs) to
identify the L. major genes encoding each of the manno-
syltransferases in this pathway (ALG1, ALG2, ALG3,
ALG9, and ALG11). Sequences that had been character-
ised in other organisms were used to build HMMs for each
gene product. These models were then used to scan pre-
dicted L. major proteins to identify the most likely candi-
date for each individual ALG gene. The functional
assignments made based on bioinformatics studies were
documented in the annotations with the appropriate evi-
dence codes (see below).
Use of literature to annotate LeishCyc genes and proteins
The functions of a number of Leishmania spp. genes have
been identified in the literature since the L. major genome
was published. As a result, these genes were not accurately
annotated in the LeishCyc automated build which relied
on the original annotation of the L. major genome project.
We used extensive searches and manual reviews of pub-
lished literature to incorporate additional Leishmania
genes, proteins, enzymes, and transporters in LeishCyc. If
a gene had been identified in L. major, the published
accession number was used to identify the gene in Leish-
Cyc. In some instances, we have judged the quality of the
published information and entered the information
accordingly. For example, 25 new annotation refinements
were proposed for the L. major genome based on weak
similarity using BLAST searches [7]. One of these genes
(LmjF31.1780) was identified as 'sphingosine N-acyl-
transferase' based on the similarity to Cryptococcus neofor-
mans sphingosine N-acyltransferase (E-value of 4 × 10-6)
although a protein BLAST search of the NCBI non-redun-
dant database returns a list with over a hundred hits with
similar or better E-value, including Trypanosoma brucei and
Trypanosoma cruzi proteins of unknown function (E-value
of ~4 × 10-70). In such cases, where we believed that fur-
ther evidence is needed to firmly support the proposed
annotation, we have quoted the literature source and the
proposed annotation, while retaining the original
'unknown' function associated with the database entry. In
cases where it was deemed that computational evidence
was sufficiently strong, the new functional annotation was
introduced with the appropriate evidence code, as
described below.
In addition to identifying published L. major genes, we
also identified L. major orthologs of enzymes and trans-
porters that have been characterized in other Leishmania
species and trypanosomatid species such as T. brucei and
T. cruzi. The L. major orthologs were identified by a sys-
tematic Needleman-Wunsch alignment of the given
sequence against L. major predicted proteins with a
processing pipeline built in-house. The results of Needle-
man-Wunsch alignment were manually reviewed for
highest similarities and, if deemed appropriate, the L.
major gene encoding the protein was annotated as the pre-
dicted ortholog (see below for the explanations of the evi-
dence code assignments). In such cases, the percent
sequence identity and/or similarity that the L. major
sequence shared with the known homologous sequence
was recorded in the LeishCyc annotation entry. For exam-
ple, the myo-inositol transporter (MIT) has been character-
ized in L. donovani, but had not been identified L. major.
The Needleman-Wunsch alignment of the L. donovani
sequence against all L. major peptides identified
LmjF24.0680 as the clear candidate for this protein in L.
major, and the peptide with the greatest similarity to L.
donovani MIT. This gene was originally annotated as 'sugar
transporter, putative' in both the original GenBank anno-
tation file and in the GeneDB entry for LmjF24.0680. We
manually annotated LmjF24.0680 as the predicted L.
major MIT, and assigned the evidence code indicating that
the inference was computational. In addition, for every
gene in LeishCyc, we have added a link to the correspond-
ing entry in GeneDB which directly connects the entries
from the two databases.
Curation of protein-linked reactions
Literature searches have identified a number of genes that
have been linked to a particular enzyme or transporter in
Leishmania  spp. or other trypanosomatids. Such genes
were identified in LeishCyc, checked as to whether they
were linked to the correct reaction(s), and, if not, the
respective entries were corrected.
Some enzymes were associated with an incorrect EC
number in the L. major Genome Project annotation file,
resulting in the enzyme being linked to incorrect reac-
tion(s). For example, the phosphomannomutase enzyme
catalyzes the reaction EC 5.4.2.8 (α-D-mannose 1-phos-
phate → mannose 6-phosphate), but in the annotation
file it was associated with EC 3.1.3.11 and thus was linked
to the EC 3.1.3.11 reaction (fructose 1,6-bisphosphate +
H2O  → fructose 6-phosphate + Pi). In the subsequent
manual curation, phosphomannomutase was removed
from the EC 3.1.3.11 reaction and linked to the EC 5.4.2.8
reaction. In total, we found 7 enzymes to be annotated
with the incorrect EC number in the L. major genome file,
and we linked these enzymes to the correct reactions.BMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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For genes not associated with an EC number in the L.
major genome annotation file, the Pathway Tools software
has attempted to link the gene based on matches of the
product name to enzyme function. For example, the gene
LmjF15.1010 was annotated as glutamate dehydrogenase
and was matched to three glutamate dehydrogenase reac-
tions each with a different EC number (EC 1.4.1.2, EC
1.4.1.3 and EC 1.4.1.4). The three reactions only differ in
the cofactor used:
EC 1.4.1.2: L-glutamate + NAD+ + H2O → α-ketoglutarate
+ ammonia + NADH
EC 1.4.1.3: L-glutamate + NAD(P)+ + H2O → α-ketogluta-
rate + ammonia + NAD(P)H
EC 1.4.1.4: L-glutamate + NADP+ + H2O → α-ketoglutar-
ate + ammonia + NADPH
LmjF15.1010 is the predicted ortholog of the L. tarentolae
mitochondrial glutamate dehydrogenase [33]. The L.
tarentolae enzyme uses NAD+ as a cofactor, but also has an
NADP+ binding site, and so, in this case, the linkage of
LmjF15.1010 to EC 1.4.1.3 was kept, and removed from
EC 1.4.1.2 and E.C. 1.4.1.4.
In certain cases, manual intervention was required to link
enzymes to the multiple reactions they catalyze. For exam-
ple, the enzyme pteridine reductase was associated with
EC 1.5.1.33 and was thus automatically linked to only
one reaction. However, this enzyme has been shown to
catalyze additional reactions in folate and biopterin
metabolism in L. major [34], and we manually linked pte-
ridine reductase to these additional (three) reactions. Sim-
ilarly, the enzyme trypanothione synthetase was
associated with EC 6.3.1.9 and automatically linked to
one reaction. However, it has been demonstrated experi-
mentally that this enzyme also catalyzes EC 6.3.1.8 [35],
thus we linked trypanothione synthetase to this reaction
as well.
For newly discovered enzymes without annotation in the
original genome project files, the required enzyme objects
were manually linked with the relevant reactions and, if
necessary, the reaction in question was created. For exam-
ple, the L. major inositol phosphorylceramide (IPC) syn-
thase gene was recently identified by [36]. This gene was
listed as a hypothetical protein in the L. major genome
annotation file. We changed its annotation in LeishCyc to
'inositol phosphorylceramide synthase', manually created
a new reaction (ceramide + L-1-phosphatidylinositol →
inositol phosphorylceramide + 1,2-diacylglycerol), and
linked the product of the gene to this reaction.
In addition to metabolic enzymes, a concerted identifica-
tion and curation of transport reactions was performed.
After the automated build, there were 23 transporters
identified in LeishCyc, but only 6 transport reactions. Fur-
thermore, many of the identified transporters had not
been assigned specific transporter identities (e.g. MIT).
Using the literature, we identified a further 26 L. major
transporters (making 49 in total) and created 31 transport
reactions [see Additional file 3].
Assignment of evidence codes and citations
The BioCyc ontology allows evidence codes to be assigned
to support assertions in the BioCyc type database [37]. If
the supporting evidence was experimental, an evidence
icon of a flask appears in the Pathway Tools software vis-
ual representation, with the assigned evidence code being
'EV-EXP' (see Figure 1). In LeishCyc this evidence code
was manually assigned to signify experimental evidence,
when the evidence came from any of the Leishmania spp.
If the supporting evidence was only computational the
evidence code 'EV-COMP' was assigned (this type of evi-
dence is shown as a computer icon). If the evidence is sup-
ported by a publication, alongside each evidence code
there is a link to the supporting publication. The code for
curated proteins shows the evidence that supports the
association of the protein with its linked reaction (i.e. for
enzymes, this is the evidence that the enzyme catalyzes a
given reaction or, for transporters, that the protein trans-
ports a particular substrate). In cases where the L. major
ortholog was identified by the LeishCyc curator from sim-
ilarity to a published sequence, the evidence code
assigned was 'EV-COMP-HINF-FN-FROM-SEQ' (human
inference of function from sequence), with additional
explanations and the percent identity that the L. major
sequence shares with the published sequence given. Cur-
rently, 208 proteins (including 2 protein complexes), 254
reactions, and 130 pathways have been assigned evidence
codes in LeishCyc, and 200 references have been added to
the database (Table 1). An example of a LeishCyc meta-
bolic pathway with evidence icons and codes as displayed
by the Pathway Tools software is shown in Figure 1.
Utility
LeishCyc provides a platform for curation, refinement,
and dissemination of information about Leishmania met-
abolic pathways incorporating extensive manual curation
and supported by the extensive query and visualization
functionality of the Pathway Tools software [25]. The
underlying BioCyc ontology provides a detailed, well-
developed ontology designed to capture biological func-
tion [14,38], and to maximize accuracy of resulting repos-
itories [13]. Furthermore, the same ontology is used in a
number of other organism-specific databases [16,19-24],
which opens the possibility for accurate cross-organism
comparisons based on the biochemical components andBMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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Example of a LeishCyc pathway with evidence codes Figure 1
Example of a LeishCyc pathway with evidence codes. This pathway for mannogen (formerly termed 'mannan') metabo-
lism is a new pathway experimentally identified in L. major [31,42]. A: the flask icon indicates that there is experimental evi-
dence for this pathway in Leishmania; B: Enzymes with names in bold type signify that there is experimental evidence that the 
Leishmania protein catalyzes the reaction shown. Enzymes in regular type have either computational evidence alone or no asso-
ciated evidence at all. Arrows and dashed lines represent reactions and polymerisation reactions, respectively.BMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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associated abstract entities, such as reactions and meta-
bolic pathways. LeishCyc enables the overlay of experi-
mental data from genome-wide studies onto the visual
representations of the L. major biochemical network. This
can be achieved by the Omics Viewer component of the
Pathway Tools software, which provides the ability to vis-
ualize high-throughput ('omics') data sets within the
LeishCyc cellular overview diagram [39]. Three examples
of LeishCyc utility in data visualization and analysis are
described below.
Visualization of proteomics data
Figure 2 shows alterations in protein expression levels
during the differentiation of L. donovani promastigotes to
in vitro differentiated (axenic) amastigotes [40], mapped
onto the LeishCyc pathways. Enzymes that are decreased
in the amastigote stage are shown in yellow while those
that are increased are shown in red. Decreases in expres-
sion levels of enzymes involved in glycolysis (3 enzymes)
and the pentose phosphate pathway (6 enzymes) are
apparent, as are increases in enzymes involved in glucone-
ogenesis (2 enzymes), oxidative phosphorylation (4
enzymes), amino acid catabolism (3 enzymes), and fatty
Overlay of proteomic data sets using the LeishCyc Omics Viewer Figure 2
Overlay of proteomic data sets using the LeishCyc Omics Viewer. Changes in the proteome of L. donovani promastig-
otes and axenic amastigotes [40] were mapped on to the Cellular Overview using the Pathway Tools Omics Viewer function-
ality. The supplied gene IDs for L. donovani/L. infantum were converted to the corresponding L. major orthologs prior to 
mapping. Lines (representing proteins) coded in red represent enzymes that were increased in amastigotes, lines in yellow rep-
resent enzymes that were decreased. Selected pathways/pathway groups are numbered as follows: 1 = amino acid biosynthesis; 
2 = glycolysis and the tricarboxylic acid (TCA) cycle; 3 = amino acid catabolism; 4 = oxidative phosphorylation; 5 = fatty acid 
beta oxidation; 6 = pentose phosphate pathway; 7 = gluconeogenesis; 8 = nucleotide biosynthesis; 9 = ergosterol biosynthesis. 
The arrows in the glycolysis and gluconeogenesis pathways are enzymes specific to these pathways [40].BMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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acid β-oxidation (5 enzymes). Additional patterns in the
data become apparent in this representation, including
decreases in some enzymes involved in nucleotide biosyn-
thesis (8 enzymes), and increases in enzymes of ergosterol
biosynthesis (9 enzymes). The use of LeishCyc greatly
reduced the time needed to produce representations of
these stage-specific metabolic changes. Furthermore, the
Omics Viewer can be used to display the time points as a
progressive series of images, creating an effect of data ani-
mation [see Additional file 4].
Visualization of metabolomics data
In the second example, LeishCyc was used to visualize
data from metabolic profiling experiments performed in
our group (Figure 3). L. mexicana MZ 379 promastigotes
were cultured in RPMI 1640 medium supplemented with
10% heat-inactivated foetal bovine serum (iFBS) at 27°C.
Log phase promastigotes were harvested approximately
two days after inoculation of the media. Axenic amastig-
otes were generated from stationary phase parasites (5–6
days after passage) by adjusting the conditioned media to
pH 5.5 with HCl and the addition of iFBS to 20% [41,42].
The adjusted culture was incubated at 33°C and amastig-
ote-like forms of the parasite were harvested on days 5 and
6. Parasite metabolism was quenched and polar metabo-
lites extracted, derivatized, and analyzed by gas chroma-
tography-mass spectrometry (GC-MS), as described
previously [43]. Figure 3 shows a colour-coded represen-
tation of changes in metabolite steady-state concentra-
tions in axenic amastigotes relative to log-phase
promastigotes. Significant changes in the steady state lev-
els of many metabolites were detected. In particular, the
levels of hexose phosphates and intermediates in glycoly-
sis were reduced, while levels of many amino acids
Overlay of metabolomic data sets using the LeishCyc Omics Viewer Figure 3
Overlay of metabolomic data sets using the LeishCyc Omics Viewer. Polar metabolites in L. mexicana promastigotes 
and axenic amastigotes were detected by GC-MS (see the main text for details). Metabolites (represented by shapes) in red 
increase in amastigote stages, while those that decrease are in yellow.BMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
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increased. Such a representation of metabolomic data in
the context of the cellular biochemical pathways is highly
useful for the observation of patterns in relative changes.
In addition, the built-in capabilities of Pathway Tools
allow one to interactively interrogate the organism meta-
bolic pathways map overlaid with experimental data
(such as those shown in Figures 2 and 3), in order to
investigate observed patterns.
Network chokepoint analysis
Chokepoint analysis has been used to prioritize potential
drug targets in the P. falciparum PlasmoCyc database [22].
Chokepoints are defined as reactions that consume
unique substrates or produce unique products, potentially
important criteria for drug target prioritization [22,44].
Pathway Tools was used to identify 324 chokepoint reac-
tions in LeishCyc. These reactions have 145 enzymes asso-
ciated with them, corresponding to 132 genes [see
Additional file 5]. This list includes a number of enzymes
previously predicted to be essential for normal growth or
infectivity. Included in the list is lanosterol 14α-demethy-
lase (LmjF11.1100), the protein target of ketoconazole,
the only clinical drug for leishmaniasis with an identified
protein target [45]. The TDR Targets database http://
www.tdrtargets.org[46] was used to identify 31 genes in
this list that do not have human orthologs [see Additional
file 5]. Interestingly, a number of the genes identified in
the chokepoint analysis of LeishCyc were also identified
in a corresponding analysis of P. falciparum [22].
Discussion and conclusion
LeishCyc captures the information about Leishmania met-
abolic pathways from genome annotations and literature
sources, and organizes this information into a structured
database supported by a well developed, publicly availa-
ble ontology [13-15,47]. LeishCyc provides a systematic
approach to organizing the evolving knowledge about
Leishmania  biochemical networks, as well as tools for
analysis, interpretation, and visualization of Leishmania
high-throughput ('omics') data in the context of meta-
bolic pathways. We believe that LeishCyc provides an
important new resource for analysis and construction of
metabolic network models for these parasites, for map-
ping species- or stage-specific changes in transcript, pro-
tein and metabolite levels, and for prioritizing potential
drug candidates by metabolic network analysis. LeishCyc
advanced search features and Omics Viewer capabilities
can be accessed through a standard web browser, and the
LeishCyc content is provided based on the Creative Com-
mons license http://creativecommons.org.
It is believed that 24 species of Leishmania infect humans.
The genome of L. major was the first to be completely
sequenced, and was used as the basis for the initial build
of LeishCyc [4]. While different species of Leishmania can
exhibit distinct trophism for different sandfly species, and
induce a spectrum of disease in humans and other mam-
malian hosts, recent sequencing projects have highlighted
a remarkable degree of synteny and conservation across
the genomes of three major pathogenic species [6,48].
Only a very limited number of genes were shown to be
present in one, but not other species of Leishmania. The
metabolic networks identified in LeishCyc are therefore
likely to be relevant to all species of Leishmania. Interest-
ingly, recent studies have suggested that species specific
differences in gene transcription or protein expression
may underlie some of the differences in biology and dis-
ease phenotypes of different Leishmania species [48-50].
As demonstrated in this study, the LeishCyc tools can be
used to visualize global changes in protein expression pat-
terns in different developmental stages, and this type of
analysis can be readily extended to identify differences in
transcript and protein expression levels in different spe-
cies.
Another important feature of LeishCyc is the capacity to
overlay metabolite profiling data sets on the predicted
metabolic networks. Leishmania and other trypanosoma-
tids are unusual in lacking a conventional network of tran-
scriptional factors and most protein encoding genes are
constitutively transcribed in all life cycle stages [51]. Con-
sequently, Leishmania metabolism may be largely regu-
lated by post-translational mechanisms. In particular, it is
likely that changes in external nutrients and scavenging
pathways, and allosteric regulation of intracellular
enzymes may play key roles in regulating metabolic proc-
esses [3]. As shown in this study, differences in the metab-
olite profiles of promastigote (insect stage) and axenic
amastigotes (mammalian-infective stages) of L. mexicana
can be mapped onto the LeishCyc metabolic network,
providing an important tool for both identifying stage-
specific changes in metabolism and assessing the extent to
which these changes correlate with transcript or protein
levels.
The LeishCyc database organizes the existing knowledge
about  Leishmania  biochemical reactions, gene products
and metabolites into metabolic pathways in a mathemat-
ically well defined manner that will serve as the founda-
tion for Leishmania systems studies, including computer-
aided reconstructions of metabolic networks. Such a
reconstruction of the L. major metabolic network has
recently been reported by Papin and colleagues [7]. The L.
major iAC560 metabolic network reconstruction included
560 genes (6.7% of the genome) and an additional 103
predicted gene associated reactions that were added for
proper functioning of the computational model. The lat-
ter remain to be experimentally verified. Interestingly, the
iAC560 metabolic network reconstruction was only par-
tially successful in predicting a number of experimentallyBMC Systems Biology 2009, 3:57 http://www.biomedcentral.com/1752-0509/3/57
Page 10 of 12
(page number not for citation purposes)
observed properties of Leishmania  metabolism, such as
minimal amino acid requirements and the potential
lethality of single gene deletions [7], highlighting signifi-
cant gaps in this model. In this respect, it is notable that
the curated LeishCyc database contains more than 1074
genes that encode enzymatic or transport reactions, even
after removal of most incomplete pathways. LeishCyc is
therefore likely to constitute an important resource for
refining metabolic reconstructions in the future. A similar
database for a related organism, T. brucei, is currently
under development [52]. A collection of such databases
will provide an unprecedented platform for detailed com-
parative studies of organisms from the Trypanosomatidae
family that can be accessed and queried programmatically
through Application Programming Interfaces (APIs)
exposed by Pathway Tools [53].
Availability and requirements
LeishCyc is available on the Internet from URL: http://
www.leishcyc.org
Abbreviations
KEGG: Kyoto Encyclopedia of Genes and Genomes; GPI:
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MS: gas chromatography-mass spectrometry; TCA: tricar-
boxylic acid.
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